Dr Daniel Kantor Highlights MS Treatments and What Is in the Pipeline
Sept 2019 The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the…
a Boster Video: New MS Drug Results: #Ofatumumab vs #Teriflunomide (ASCLEPIOS trial)
Aaron Boster MD In this video I share brand new MS drug results, comparing a new B-cell killer (Ofatumamab) to…
Stuart Schlossman
Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients…
Stuart Schlossman
EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis
EVOLUTION RMS 1 and 2 pivotal Phase III trials will investigate the efficacy and safety of evobrutinib in relapsing multiple…
Stuart Schlossman
MS Patients Should Be Informed about Pregnancy Risks and Family Planning, Experts Say
SEPTEMBER 11, 2019 – BY ANA PENA, PHD of Medical News Today While pregnancy does not appear to affect the disease…
Stuart Schlossman
Ponesimod Bests Aubagio in Head-to-Head MS Trial
Investigational drug reduces annual relapse rate, shows effects on fatigue by Judy George, Senior Staff Writer, MedPage TodaySeptember 12, 2019 STOCKHOLM —…
Stuart Schlossman
#ECTRIMS2019 – Data Shows Ublituximab’s Long-term Safety in Relapsing MS, TG Therapeutics Announced
EXPERIMENTAL TREATMENTS FOR MS » UBLITUXIMAB (TGTX-1101) Ublituximab (TGTX-1101) is a glycoengineered anti-CD20 monoclonal antibody being developed by TG Therapeutics as a potential treatment for relapsing…
Stuart Schlossman
Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– – Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in…
Stuart Schlossman
Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS
Published: Sep 04, 2019 Sept. 4, 2019 05:00 UTC Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal…
Stuart Schlossman
Join us (in Columbus, OH) for a Special Roundtable discussion: “MS Conversations NOW” , with Aaron Boster, MD and an MS Patient Advocate
REGISTRATION NOW open for MS event called “MS Conversations NOW” RSVP for this Special RoundTable discussion with two special people…
Stuart Schlossman
